about
Genetically modified tumour vaccines--where we are today.From microarrays to new therapeutic approaches in bladder cancer.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trialSHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).The Polish Cancer Anemia Survey (POLCAS): a retrospective multicenter study of 999 cases.How Long Are Cancer Patients Waiting for Oncological Therapy in Poland?Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.Genetically modified tumour vaccines (GMTV) in melanoma clinical trialsThe Waiting Time of Prostate Cancer Patients in PolandExpression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinomaThe 14th European Immunology Meeting--EFIS 2000. 23-27 September 2000, Poznañ, PolandClinical trials of active cancer immunotherapyConsensus statement on a screening programme for the detection of early lung cancer in Poland
P50
Q33599134-028A4B80-30C1-4204-BFE8-0ED3121F5C6AQ35073307-15928643-0DEB-41FA-A949-843A00AE775DQ36012730-65BC4EF5-6C6C-4717-B24A-BF04D3971426Q36243993-2C73F431-C12E-48D5-8EF2-A56C71CAEC9EQ37034249-219C23FE-CCF0-40F0-BA64-B6BD3EA124D0Q42997441-03536993-032D-4C3B-8C7E-6B75D5A410C9Q44991597-967187F4-7116-4AB4-B809-792F6CDD219AQ47574245-2F3B072D-E98E-424F-81D0-9A7605604724Q50613206-1BC12C32-1B99-4F05-A990-EB334D8AA22FQ51145466-4C4D26C3-2109-419E-9CD7-0C79F00322ECQ53647674-427D3B6B-B2D4-4249-9D12-976A2DA49C5DQ62658886-334C909B-F362-4A5C-A2FE-521F5EE61A34Q64227359-6A3417ED-4B08-41D8-A1B7-4E8AC925CFE2Q73798154-D3A0F5CF-A4AF-42F0-9C8E-181998DB7028Q77304562-58417B48-446A-475A-90B6-64F227D36A87Q80765417-61C7DAEA-CAA0-4D16-98E6-20458EB99E6DQ87910604-12002DFA-4581-4D49-B723-385703865F3E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sergiusz Nawrocki
@ast
Sergiusz Nawrocki
@en
Sergiusz Nawrocki
@es
Sergiusz Nawrocki
@nl
Sergiusz Nawrocki
@sl
type
label
Sergiusz Nawrocki
@ast
Sergiusz Nawrocki
@en
Sergiusz Nawrocki
@es
Sergiusz Nawrocki
@nl
Sergiusz Nawrocki
@sl
prefLabel
Sergiusz Nawrocki
@ast
Sergiusz Nawrocki
@en
Sergiusz Nawrocki
@es
Sergiusz Nawrocki
@nl
Sergiusz Nawrocki
@sl
P106
P1153
55488989400
P31
P496
0000-0001-6225-6528